Evidence map›Paper›PMID 34388977›Full record

Trial reportBMC cancer2021

Sniffer dogs can identify lung cancer patients from breath and urine samples.

Charlotte Feil, Frank Staib, Martin R Berger, Thorsten Stein, Irene Schmidtmann, Andreas Forster, Carl C Schimanski

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Charlotte Feil *2nd Department of Internal Medicine, Municipal Hospital Darmstadt, Grafenstraße 9, 64283, Darmstadt, Germany.
Frank Staib *2nd Department of Internal Medicine, Municipal Hospital Darmstadt, Grafenstraße 9, 64283, Darmstadt, Germany.
Martin R BergerToxicology and Chemotherapy Unit, German Cancer Research Center, Heidelberg, Germany.
Thorsten Stein2nd Department of Internal Medicine, Municipal Hospital Darmstadt, Grafenstraße 9, 64283, Darmstadt, Germany.
Irene SchmidtmannInstitute for Medical Biostatistics, Epidemiology and Informatics, Johannes Gutenberg-University Mainz, Mainz, Germany.
Andreas ForsterPulmonologist's Office Darmstadt, Darmstadt, Germany.
Carl C Schimanski2nd Department of Internal Medicine, Municipal Hospital Darmstadt, Grafenstraße 9, 64283, Darmstadt, Germany. Carl.Schimanski@mail.klinikum-darmstadt.de.
Klinikum Darmstadt · DEFacility for Antiproton and Ion Research · DEHeidelberg University · DEJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is the most common oncological cause of death in the Western world. Early diagnosis is critical for successful treatment. However, no effective screening methods exist. A promising approach could be the use of volatile organic compounds as diagnostic biomarkers. To date there are several studies, in which dogs were trained to discriminate cancer samples from controls. In this study we evaluated the abilities of specifically trained dogs to distinguish samples derived from lung cancer patients of various tumor stages from matched healthy controls.

methodsThis single center, double-blind clinical trial was approved by the local ethics committee, project no FF20/2016. The dog was conditioned with urine and breath samples of 36 cancer patients and 150 controls; afterwards, further 246 patients were included: 41 lung cancer patients comprising all stages and 205 healthy controls. From each patient two breath and urine samples were collected and shock frozen. Only samples from new subjects were presented to the dog during study phase randomized, double-blinded. This resulted in a specific conditioned reaction pointing to the cancer sample.

resultsUsing a combination of urine and breath samples, the dog correctly predicted 40 out of 41 cancer samples, corresponding to an overall detection rate of cancer samples of 97.6% (95% CI [87.1, 99.9%]). Using urine samples only the dog achieved a detection rate of 87.8% (95% CI [73.8, 95.9%]). With breath samples, the dog correctly identified cancer in 32 of 41 samples, resulting in a detection rate of 78% (95% CI [62.4, 89.4%]).

conclusionsIt is known from current literature that breath and urine samples carry VOCs pointing to cancer growth. We conclude that olfactory detection of lung cancer by specifically trained dogs is highly suggestive to be a simple and non-invasive tool to detect lung cancer. To translate this approach into practice further target compounds need to be identified.

Indexed as

BiomarkersExhalationLung NeoplasmsOlfactory PerceptionVolatile Organic CompoundsWorking DogsAnimalsBronchoscopesDogsEarly Detection of CancerHumansRespiratory Function TestsSensitivity and SpecificityTomography, X-Ray ComputedBiomarkersVolatile Organic CompoundsLung cancerOlfactory detectionVolatile organic compounds

Identifiers

PMID34388977
PMCPMC8362224
OpenAlexW3191280828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.